These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 38169778)

  • 1. Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study.
    Wu XK; Yang LF; Chen YF; Chen ZW; Lu H; Shen XY; Chi MH; Wang L; Zhang H; Chen JF; Huang JY; Zeng YY; Yan ML; Zhang ZB
    EClinicalMedicine; 2024 Jan; 67():102367. PubMed ID: 38169778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective, single-arm, phase II study.
    Chen Y; Zhang J; Hu W; Li X; Sun K; Shen Y; Zhang M; Wu J; Gao S; Yu J; Que R; Zhang Y; Yang F; Xia W; Zhang A; Tang X; Bai X; Liang T
    Signal Transduct Target Ther; 2024 Oct; 9(1):280. PubMed ID: 39384742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study.
    Wu JY; Yin ZY; Bai YN; Chen YF; Zhou SQ; Wang SJ; Zhou JY; Li YN; Qiu FN; Li B; Yan ML
    J Hepatocell Carcinoma; 2021; 8():1233-1240. PubMed ID: 34676181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Lenvatinib and Anti-PD-1 Antibodies for Unresectable Hepatocellular Carcinoma: A Retrospective Analysis.
    Wu SJ; Ruan DD; Wu QY; Tang Y; Zhang JH; Cai SL; Zhou YF; Luo JW; Fang ZT
    J Hepatocell Carcinoma; 2023; 10():807-820. PubMed ID: 37292114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of transcatheter arterial chemoembolization-lenvatinib sequential therapy for patients with unresectable hepatocellular carcinoma: a single-arm clinical study.
    Chen R; Li L; Li Y; Song K; Shen C; Ma P; Wang Z
    J Gastrointest Oncol; 2022 Jun; 13(3):1367-1375. PubMed ID: 35837188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World.
    Li X; Fu Z; Chen X; Cao K; Zhong J; Liu L; Ding N; Zhang X; Zhai J; Qu Z
    Front Oncol; 2022; 12():950266. PubMed ID: 35860582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study.
    Tang Z; Bai T; Wei T; Wang X; Chen J; Ye J; Li S; Wei M; Li X; Lin Y; Tang J; Li L; Wu F
    BMC Cancer; 2024 Jun; 24(1):717. PubMed ID: 38862932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of Lenvatinib-based combination therapies for patients with unresectable hepatocellular carcinoma: a single center retrospective study.
    Huang J; Wang ZG; Tao QF; Yang Y; Yuan SX; Gu FM; Liu H; Pan ZY; Jiang BG; Lau WY; Zhou WP
    Front Immunol; 2023; 14():1198562. PubMed ID: 37483609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A two-center retrospective study.
    Sun B; Zhang L; Sun T; Ren Y; Cao Y; Zhang W; Zhu L; Guo Y; Gui Y; Liu F; Chen L; Xiong F; Zheng C
    Front Oncol; 2022; 12():982948. PubMed ID: 36172158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial.
    Kudo M; Ueshima K; Saeki I; Ishikawa T; Inaba Y; Morimoto N; Aikata H; Tanabe N; Wada Y; Kondo Y; Tsuda M; Nakao K; Ito T; Hosaka T; Kawamura Y; Kuzuya T; Nojiri S; Ogawa C; Koga H; Hino K; Ikeda M; Moriguchi M; Hisai T; Yoshimura K; Furuse J; Arai Y
    Liver Cancer; 2024 Feb; 13(1):99-112. PubMed ID: 38344448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma.
    Liu QQ; Wang XX; Ji H; Dou QY; Zhang HM
    Med Oncol; 2024 Mar; 41(5):91. PubMed ID: 38526607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma.
    Wang YY; Yang X; Wang YC; Long JY; Sun HS; Li YR; Xun ZY; Zhang N; Xue JN; Ning C; Zhang JW; Zhu CP; Zhang LH; Yang XB; Zhao HT
    World J Gastroenterol; 2023 Mar; 29(10):1614-1626. PubMed ID: 36970591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma: A Single Center Experience.
    Pan X; Wu SJ; Tang Y; Zhou YF; Luo JW; Fang ZT
    J Hepatocell Carcinoma; 2023; 10():883-892. PubMed ID: 37324411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma Converted by Transcatheter Arterial Chemoembolization Combined with Lenvatinib plus Anti-PD-1 Antibodies: A Multicenter Retrospective Study.
    Wu JY; Zhang ZB; Zhou JY; Ke JP; Bai YN; Chen YF; Wu JY; Zhou SQ; Wang SJ; Zeng ZX; Li YN; Qiu FN; Li B; Yan ML
    Liver Cancer; 2023 Aug; 12(3):229-237. PubMed ID: 37767067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcatheter arterial chemoembolisation combined with lenvatinib and cabozantinib in the treatment of advanced hepatocellular carcinoma.
    Liu H; Gan XM; Sun JM; Yang Q; Zhang DZ; Zuo YQ; Liu FL; Li B; Tan QL; Zhang J
    Int Immunopharmacol; 2024 Mar; 130():111510. PubMed ID: 38422766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma.
    Teng Y; Ding X; Li W; Sun W; Chen J
    Technol Cancer Res Treat; 2022; 21():15330338221075174. PubMed ID: 35313780
    [No Abstract]   [Full Text] [Related]  

  • 17. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.
    Fu Z; Li X; Zhong J; Chen X; Cao K; Ding N; Liu L; Zhang X; Zhai J; Qu Z
    Hepatol Int; 2021 Jun; 15(3):663-675. PubMed ID: 33877527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.
    Zhang W; Tong S; Hu B; Wan T; Tang H; Zhao F; Jiao T; Li J; Zhang Z; Cai J; Ye H; Wang Z; Chen S; Wang Y; Li X; Wang F; Cao J; Tian L; Zhao X; Chen M; Wang H; Cai S; Hu M; Bai Y; Lu S
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of low-dose cyclophosphamide combined with lenvatinib, pembrolizumab and TACE for unresectable hepatocellular carcinoma: A single-center, prospective, single-arm clinical trial.
    Ren Y; Li Y; Cao M; Tang Y; Yuan F; Yang G; He Z; Shi Z; Su X; Yao Z; Deng M
    Chin J Cancer Res; 2024 Apr; 36(2):114-123. PubMed ID: 38751440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of lenvatinib-transcatheter arterial chemoembolisation sequential therapy followed by surgical resection for intermediate-stage hepatocellular carcinoma beyond Up-to-7 criteria: a study protocol for a multicentre, single-arm, prospective study.
    Oshita K; Kobayashi T; Namba Y; Fukuhara S; Matsubara K; Takei D; Nakano R; Okamoto W; Sakai H; Tanimine N; Nakahara T; Kuroda S; Tahara H; Ohira M; Kawaoka T; Ide K; Imamura M; Aikata H; Ohdan H
    BMJ Open; 2023 Oct; 13(10):e073797. PubMed ID: 37798025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.